Select a medication above to begin.
paclitaxel
generic
Black Box Warnings .
Appropriate Use
admin. only under supervision of physician experienced in cancer chemotherapy in adequate medical facility to manage complications
Anaphylaxis/Severe Hypersensitivity Rxn
pretreat all pts w/ corticosteroids, diphenhydramine, and H2 antagonists; 2-4% incidence of rxns incl. dyspnea and hypotension requiring tx, angioedema, generalized urticaria; fatal rxns have occurred despite premeds; do not rechallenge after severe hypersensitivity rxn
Myelosuppression
avoid if baseline ANC <1500 cells/mm^3 in solid tumor pts or if ANC <1000 cells/mm^3 in AIDS-related Kaposi sarcoma pts; monitor CBC; neutropenia may be severe and result in infection
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: not interchangeable w/ albumin-bound paclitaxel formulations; do not substitute on a mg to mg basis
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
ovarian CA, advanced
- [first-line tx]
- Dose: 135 mg/m^2/dose IV over 24h x1 on day 1 of 21-day cycle; Alt: 175 mg/m^2/dose IV over 3h x1 on day 1 of 21-day cycle; Info: use w/ cisplatin or carboplatin
- [recurrent dz]
- Dose: 135 mg/m^2/dose IV over 3h x1 on day 1 of 21-day cycle; Alt: 175 mg/m^2/dose IV over 3h x1 on day 1 of 21-day cycle; Info: part of multi-drug chemo regimen
node-positive breast CA, adjuvant tx
- [175 mg/m^2/dose IV over 3h x1 on day 1 of 21-day cycle]
- Info: give x4 cycles; part of multi-drug chemo regimen
breast CA, refractory metastatic or relapsed
- [175 mg/m^2/dose IV over 3h x1 on day 1 of 21-day cycle]
- Info: part of multi-drug chemo regimen
non-small cell lung CA
- [135 mg/m^2/dose IV over 24h x1 on day 1 of 21-day cycle]
- Info: use w/ cisplatin or carboplatin
Kaposi sarcoma, AIDS-assoc.
- [100 mg/m^2/dose IV over 3h x1 on day 1 of 14-day cycle]
- Alt: 135 mg/m^2/dose IV over 3h x1 on day 1 of 21-day cycle; Info: not 1st line tx
renal dosing
- [see below]
- renal impairment: no adjustment
- HD: no adjustment; no supplement; PD: not defined
hepatic dosing
- [if usual regimen 135 mg/m^2/dose over 24h]
- AST or ALT 2-9.9x ULN and bilirubin <1.6: give 100 mg/m^2/dose; AST or ALT <10x ULN and bilirubin 1.6-7.5: give 50 mg/m^2/dose; AST or ALT >10x ULN or bilirubin >7.5: avoid use
- [if usual regimen 175 mg/m^2/dose over 3h]
- AST or ALT <10x ULN and bilirubin 1.26-2x ULN: give 135 mg/m^2/dose; AST or ALT <10x ULN and bilirubin 2.01-5x ULN: give 90 mg/m^2/dose; AST or ALT>10x ULN or bilirubin >5x ULN: avoid use
- [all other regimens]
- hepatic impairment: decr. usual dose, amount not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.